With both compounds reducing energy intake (tirzepatide through appetite) and mobilizing stored energy (AOD 9604 through lipolysis), the body is working harder to maintain homeostasis
Foundayo (Orforglipron): Recently approved, Foundayo is the newest oral GLP-1 weight loss solution
36 Because appetite reduction is common with GLP-1 agonists, and many individuals on GLP-1 therapies are counseled to prioritize protein and/or follow a ketogenic diet to support muscle maintenance during weight loss, fiber intake is often reduced significantly as fruits, vegetables and grains are eliminated
Yes, our BPC-157 products are also formulated without gluten, dairy, and soy
Metformin is an oral medication that is gaining some traction, but like Ozempic, it is only FDA-approved to treat type 2 diabetes